INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRENEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (
NASDAQ: FTRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
1 Cash-Producing Stock That Stand Out and 2 to Be Wary OfWhile strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRENEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (
NASDAQ: FTRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRENEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (
NASDAQ: FTRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Fortrea Announces Date for First Quarter 2025 Financial Results and Conference CallDURHAM, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter 2025 financial results before the market opens on Monday, May 12, 2025. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRENEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (
NASDAQ: FTRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
1 Oversold Stock Primed to Rebound and 2 to Approach with CautionHitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fortrea Holdings Inc. - FTRENEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (
NASDAQ: FTRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRENEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (
NASDAQ: FTRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRENEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (
NASDAQ: FTRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRENEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (
NASDAQ: FTRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services StocksThe end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (
NYSE:IQV) and the rest of the drug development inputs & services stocks fared in Q4.
Bragar Eagel & Squire, P.C. Is Investigating Fortrea and Ibotta and Encourages Investors to Contact the FirmNEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fortrea Holdings Inc. (
NASDAQ:FTRE) and Ibotta, Inc. (
NYSE:IBTA). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services StocksEarnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (
NYSE:WST) and its peers.
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs PeersWrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (
NASDAQ:MEDP) and its peers.
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (
NASDAQ: FTRE) investors concerning the Company’s possible violations of the federal securities laws.
Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith continues its investigation on behalf of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (
NASDAQ: FTRE) investors concerning the Company’s possible violations of federal securities laws.
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz continues its investigation of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (
NASDAQ: FTRE) on behalf of investors concerning the Company’s possible violations of federal securities laws.
FORTREA ALERT: Bragar Eagel & Squire, P.C. is Investigating Fortrea Holdings Inc. on Behalf of Fortrea Stockholders and Encourages Investors to Contact the FirmNEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fortrea Holdings Inc. (“Fortrea” or the “Company”) (
NASDAQ:FTRE) on behalf of Fortrea stockholders. Our investigation concerns whether Fortrea has violated the federal securities laws and/or engaged in other unlawful business practices.
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)Let’s dig into the relative performance of Fortrea (
NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season.
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services StocksEarnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (
NASDAQ:PACB) and its peers.
Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services StocksAs the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at drug development inputs & services stocks, starting with UFP Technologies (
NASDAQ:UFPT).
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services StocksEarnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (
NASDAQ:AZTA) and its peers.
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The PackAs the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (
NASDAQ:RGEN) and its peers.
